secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001753926-25-000526
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical reports FY2024 net loss $23.5M; obesity implant trials on track for mid-2025 data
--------------------------------------------------------------------------------

- FY2024 net loss $23.5M vs $25.7M YoY; cash $19.7M at Dec 31, 2024.
- LIBERATE-1 (NPM-115 exenatide) fully enrolled; top-line data expected mid-2025.
- NPM-139 (semaglutide) preclinical data positive, once-yearly dosing potential.
- Closed $8.25M equity financing on March 27, 2025 to fund into Q2 2026.
- Plans to spin off Cortigent subsidiary as independent public company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625000526/0001753926-25-000526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625000526/vani-20250331.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer